DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
DERM logo

Journey Medical Corporation Stock Price

NasdaqCM:DERM Community·US$208.3m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 19 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

DERM Share Price Performance

US$7.36
0.19 (2.65%)
​
US$13.50
Fair Value
US$7.36
0.19 (2.65%)
45.5% undervalued intrinsic discount
US$13.50
Fair Value
Price US$7.36
AnalystConsensusTarget US$13.50
AnalystHighTarget US$16.00
AnalystLowTarget US$13.00
Wed, 24 Jun 26
Fair ValueUS$13.50
Share Pricen/a

DERM Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$13.5 45.5% undervalued intrinsic discount

Rising Global Dermatologic Demand Will Fuel Future Success

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$16 54.0% undervalued intrinsic discount

Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$13 43.4% undervalued intrinsic discount

Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DERM logo
Journey Medical
43.4% undervalued intrinsic discount

Slow Reimbursement And Competitive Pressures Will Challenge Dermatology Prescriptions Yet Support Gradual Improvement

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 14 Aug
Read Narrative
DERM logo
Journey Medical
45.5% undervalued intrinsic discount

Rising Global Dermatologic Demand Will Fuel Future Success

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 24 Jun
Read Narrative
DERM logo
Journey Medical
54.0% undervalued intrinsic discount

Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 26 Mar
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
DERM logo

DERM: Positive Operating Profit Will Support Ongoing Prescription And Pricing Momentum

Fair Value: US$13 43.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
DERM logo

DERM: Expanded Access And Parent Cash Backing Will Support Future Value

Fair Value: US$13.5 45.5% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
DERM logo

Rosacea Market Tailwinds And Payer Access Will Drive Durable Long Term Dermatology Upside

Fair Value: US$16 54.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued with high growth potential.

0 Risks
5 Rewards
View Full Analysis

Journey Medical Corporation Key Details

US$68.2m

Revenue

US$23.6m

Cost of Revenue

US$44.6m

Gross Profit

US$50.7m

Other Expenses

-US$6.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.22
65.45%
-8.95%
79.3%
View Full Analysis

About DERM

Founded
2014
Employees
58
CEO
Claude Maraoui
WebsiteView website
journeymedicalcorp.com

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Recent DERM News & Updates

User avatar
Narrative Update • Aug 14

DERM: Positive Operating Profit Will Support Ongoing Prescription And Pricing Momentum

Analysts have lifted the fair value estimate for Journey Medical from $11.00 to $13.00. They point to higher profit margin assumptions, a slightly higher discount rate, and recent research that highlights stronger prescription trends, better net revenue per script, and the company's first reported positive GAAP operating profit as key supports for the higher target.

Recent updates

No updates

Journey Medical Corporation Competitors

STTK logo

Shattuck Labs

Symbol: NasdaqGS:STTK
Market cap: US$622.3m
CRMD logo

CorMedix

Symbol: NasdaqGM:CRMD
Market cap: US$615.0m
ALLO logo

Allogene Therapeutics

Symbol: NasdaqGS:ALLO
Market cap: US$615.0m
AQST logo

Aquestive Therapeutics

Symbol: NasdaqGM:AQST
Market cap: US$612.5m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide